Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney

Clinical Cancer Research

Volumn 13, Issue 15, 2007, Pages 4360-4364

  Little, Suzanne E ^a   Bax, Dorine A ^a   Rodriguez Pinilla, Maria ^b   Natrajan, Rachael ^a   Messahel, Boo ^a   Pritchard Jones, Kathy ^a   Vujanic, Gordan M ^c   Reis Filho, Jorge S ^b   Jones, Chris ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; METHIONINE; PROTEIN KINASE B; THREONINE;

ANAPLASTIC CARCINOMA; ARTICLE; CLEAR CELL SARCOMA; EGFR GENE; ENZYME PHOSPHORYLATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFANT; KIDNEY SARCOMA; MAJOR CLINICAL STUDY; NEPHROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTEN GENE;

CHILD, PRESCHOOL; GENE AMPLIFICATION; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; INFANT; KIDNEY NEOPLASMS; MUTATION; NEPHROMA, MESOBLASTIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RHABDOID TUMOR; SARCOMA, CLEAR CELL; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; WILMS TUMOR;

EID: 34547691202     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0398     Document Type: Article

References (20)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptorsin human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
2. Ciardiello F, De Vita F, Orditura M, Tortora G. The role of EGFR inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 2004;16:130-5.
3. Glover KY, Perez-Soler R, Papadimitradopoulou VA. A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer. Semin Oncol 2004;31:83-92.
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
5. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
6. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-37.
7. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97:880-7.
8. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24.
9. Daw NC, Furman WL, Stewart CF, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2005;23:6172-80.
10. Cutcliffe C, Kersey D, Huang CC, et al. Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin Cancer Res 2005;11:7986-94.
11. Reis-Filho JS, Milanezi F, Carvalho S, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005;7:R1028-35.
12. Perren A, Komminoth P, Saremaslani P, et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumorsco mpared to normal islet cells. Am J Pathol 2000;157:1097-103.
13. Kwak EL, Jankowski J, Thayer SP, et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res20 06;12:4283-7.
14. Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005;37:1315-6.
15. Seibel NL, Li S, Breslow NE, et al. Effect of duration of treatment on treatment outcome for patients with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group. J Clin Oncol 2004;22:468-73.
16. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
17. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
18. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23.
19. Schuster AE, Schneider DT, Fritsch MK, Grundy P, Perlman EJ. Genetic and genetic expression analyses of clear cell sarcoma of the kidney. Lab Invest 2003;83:1293-9.
20. Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor overcomes resistance caused by amutation of the epidermal growth factor receptor. Cancer Res 2005;65:7096-101.